- Home
- APLS vs BHC Comparison
APLS vs BHC Comparison
Compare APLS & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- BHC
- Stock Information
- Founded
- APLS 2009
- BHC N/A
- Country
- APLS United States
- BHC Canada
- Employees
- APLS N/A
- BHC N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- BHC Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- BHC Health Care
- Exchange
- APLS Nasdaq
- BHC Nasdaq
- Market Cap
- APLS 2.3B
- BHC 2.0B
- IPO Year
- APLS 2017
- BHC N/A
- Fundamental
- Price
- APLS $17.30
- BHC $4.59
- Analyst Decision
- APLS Buy
- BHC Hold
- Analyst Count
- APLS 19
- BHC 5
- Target Price
- APLS $39.06
- BHC $7.20
- AVG Volume (30 Days)
- APLS 2.7M
- BHC 2.6M
- Earning Date
- APLS 05-07-2025
- BHC 04-30-2025
- Dividend Yield
- APLS N/A
- BHC N/A
- EPS Growth
- APLS N/A
- BHC N/A
- EPS
- APLS N/A
- BHC N/A
- Revenue
- APLS $775,839,000.00
- BHC $9,731,000,000.00
- Revenue This Year
- APLS $12.25
- BHC $4.92
- Revenue Next Year
- APLS $21.08
- BHC $2.36
- P/E Ratio
- APLS N/A
- BHC N/A
- Revenue Growth
- APLS 48.04
- BHC 8.53
- 52 Week Low
- APLS $16.65
- BHC $3.96
- 52 Week High
- APLS $43.99
- BHC $9.85
- Technical
- Relative Strength Index (RSI)
- APLS 34.14
- BHC 34.85
- Support Level
- APLS $16.65
- BHC $4.63
- Resistance Level
- APLS $20.75
- BHC $4.86
- Average True Range (ATR)
- APLS 1.09
- BHC 0.25
- MACD
- APLS 0.14
- BHC -0.00
- Stochastic Oscillator
- APLS 15.85
- BHC 6.02
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.